Organon gives Sun Pharma scale and reach, but challenge lies in integration, execution – News Air Insight

ET Intelligence Group: The acquisition of Organon & Co by Sun Pharmaceutical Industries, valued at $11.75 billion, implies an enterprise value-to-sales (EV/Sales) multiple of about 1.9 times, significantly below Bloomberg’s comparable median of 4.8 times. It is also lower than the EV/sales of 6.5 times at which Torrent Pharmaceuticals’ acquired JB Chemicals & Pharmaceuticals in June 2025. While Sun Pharma’s deal appears inexpensive, it also reflects Organon’s muted growth profile, with revenues largely flat over the past four years, underscoring the execution challenges for Sun Pharma while it attempts to bring Organon back on the growth path.

Read more: Sun Pharma: How a small Kolkata trader became a global buyout artist

Margin-wise, both the businesses seem to be at par with an Ebitda margin of 29-30% during the last financial year. This may support consolidated margins over the long term even if near-term margins come under some pressure.

Nearly 60% of Organon’s revenue comes from established brands, with women’s health contributing about 28% and the balance from biosimilars. For Sun Pharma, the acquisition offers an opportunity to grow these segments where its current exposure remains limited, while also lifting the share of innovative medicines to about 27% of the combined portfolio from 20% earlier.

Beyond portfolio diversification, Organon adds significant global scale and commercial reach. The company operates six manufacturing facilities across Brazil, UK, Belgium, Netherlands, Indonesia and Mexico, and has a commercial presence in more than 140 countries, with the US and Europe as its largest markets. At a time when Sun Pharma’s access to the US has been constrained by regulatory concerns at its Halol plant, the deal provides a ready entry into the US market through Organon’s established presence. In addition, Organon’s operations in China, Canada and Brazil further strengthen Sun Pharma’s global reach.

Also Read: Sun Pharma to acquire Organon for $12.5 bn, its biggest till dateThe key concern is the sharp rise in debt at Sun Pharma. While the company is currently net-cash positive, it will raise about $9.25-9.75 billion to fund the acquisition, which is expected to push net debt-to-Ebitda to around 2.3 times. However, Sun Pharma expects cost synergies of more than $350 million over the next 2-4 years, driven by its branded generics to revive Organon’s established brands, while scaling the biosimilars platform and pursuing in-licensing opportunities through Organon’s global reach.

Overall, while the acquisition comes with near-term risks to growth, integration and leverage, it offers Sun Pharma scale, diversification and a broader global footprint, positioning the company for a potentially stronger and more balanced growth profile over the longer term, provided execution risks are managed effectively. Sun Pharma’s stock closed 7% higher at ₹1,731 on the NSE.